Form 4: Adicet Bio CEO Chen Schor Acquires Stock Options
SEC Form 4 Filing
Chen Schor, President & CEO of Adicet Bio, Inc., reports acquisition of stock options on January 31, 2025.
Summary
- Chen Schor, the President and CEO of Adicet Bio, Inc., filed a Form 4 on February 4, 2025.
- The filing reports a transaction that occurred on January 31, 2025, where Schor acquired 763,829 stock options with an exercise price of $0.885.
- These options vest monthly over 48 months from the grant date, contingent upon continued service with the company.
- Following the reported transaction, Schor directly owns 763,829 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports the acquisition of stock options, a common practice. It doesn't inherently indicate positive or negative performance.
Positives
- The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The acquisition of stock options by the CEO could potentially impact shareholder value depending on the future performance of the company.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of stock option acquisition. |
| 02/04/2025 | Date of Form 4 filing. |
| 01/30/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.